Intermittent Explosive Disorder Completed Phase 4 Trials for Guanfacine (DB01018)

IndicationStatusPhase
DBCOND0030738 (Intermittent Explosive Disorder)Completed4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02048241Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive DisorderTreatment